BRNS

Stats

Summary

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit

Market Cap: 104 Million

Primary Exchange: NASDAQ

Website: vaccitech.co.uk

Shares Outstanding: 38.6 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.9118552772019449

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 40 trading days

From: 2024-01-02 To: 2024-03-07

Lowest Point: